Richard Lafayette, MD, FACP, Director of the Stanford Glomerular Disease Center, and Rheumatologist at Stanford Health Care, describes the latest clinical trial assessing Nefecon (budesonide delayed-release capsules) for immunoglobulin A (IgA) nephropathy treatment.
The accumulation of IgA deposits in the kidneys characterizes IgA nephropathy (Berger’s disease), a rare kidney disease. The buildup of IgA deposits inflames and damages the glomeruli, causing hematuria and proteinuria. This damage may lead to scarring of the nephrons which progresses slowly over many years. Eventually, IgA nephropathy can lead to end-stage kidney disease.
As Dr. Lafayette states, the phase 3 NefIgArd trial evaluating Nefecon in patients with IgA nephropathy met its primary endpoint demonstrating a highly statistically significant benefit over placebo in eGFR and the efficacy was maintained for up to two years.
To learn more about IgA nephropathy and other rare kidney diseases, visit checkrare.com/diseases/kidney